Table 1 Baseline demographic and characteristics of enrolled subjects from two clinical trials conducted in subjects with primary RLS
Characteristic | XP052 (n = 220) | XP053 (n = 320) | All (n = 540)2 |
|---|---|---|---|
Age | |||
Mean (SD) | 51.5 (12.75) | 49.3 (12.55) | 50.2 (12.66) |
Female (n, %) | 131 (59.5%) | 189 (59.1%) | 320 (59.3%) |
Race (n, %) | |||
White or Caucasian | 212 (96.4) | 303 (94.7) | 515 (95.4) |
Black or African-American | 5 (2.3) | 5 (1.6) | 10 (1.9) |
Other | 3 (1.3) | 12 (3.7) | 15 (2.7) |
Ethnicity (n, %) | |||
Hispanic or Latino | 8 (3.6) | 25 (7.8) | 33 (6.1) |
Non-Hispanic or Latino | 212 (96.4) | 295 (92.2) | 507 (93.9) |
Treatment (n, %) | |||
1200 mg | 113 (51.4) | 111 (34.7) | 224 (41.5) |
600 mg | 0 | 113 (35.3) | 113 (20.9) |
Placebo | 107 (48.6) | 96 (30.0) | 203 (37.6) |
RLS Severity (n, %)1 | |||
Mild | 0 | 0 | 0 |
Moderate | 82 (37.3) | 102 (31.9) | 184 (34.1) |
Severe | 121 (55.0) | 193 (60.3) | 314 (58.1) |
Very severe | 17 (7.7) | 25 (7.8) | 42 (7.8) |